Efficacy and Safety of Abiraterone Acetate in an Elderly Patient Subgroup (Aged 75 and Older) with Metastatic Castration-resistant Prostate Cancer After Docetaxel-based Chemotherapy

Autor:	Fred Saad, Arturo Molina, Thian Kheoh, Michael Marberger, C. M. Haqq, Karim Fizazi, Kim N. Chi, Peter F.A. Mulders, Jinhui Li, Celestia S. Higano
Rok vydání:	2014
Předmět:	Adult Male Oncology medicine.medical_specialty Urology medicine.medical_treatment Abiraterone Acetate Hypokalemia Docetaxel Placebo Disease-Free Survival chemistry.chemical_compound Prostate cancer Double-Blind Method Internal medicine Antineoplastic Combined Chemotherapy Protocols Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15] Post-hoc analysis medicine Humans Fatigue Aged Aged 80 and over Chemotherapy Proportional hazards model business.industry Hazard ratio Age Factors Abiraterone acetate Steroid 17-alpha-Hydroxylase Middle Aged Prostate-Specific Antigen medicine.disease Surgery Androstadienes Survival Rate Prostatic Neoplasms Castration-Resistant chemistry Hypertension Prednisone Taxoids business medicine.drug
Zdroj:	European Urology, 65, 875-83 European Urology, 65, 5, pp. 875-83
ISSN:	0302-2838
Popis:	Item does not contain fulltext BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) is a disease that primarily affects older men. Abiraterone acetate (AA), a selective androgen biosynthesis inhibitor, in combination with low-dose prednisone (P) improved overall survival (OS) in a randomised trial in mCRPC progressing after docetaxel versus placebo (PL) plus P. OBJECTIVE: To examine the efficacy and safety of AA plus P versus PL plus P in subgroups of elderly (aged >/=75 yr) (n=331) and younger patients (
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b263a7eccd855faf66a7c935a726ed9 https://doi.org/10.1016/j.eururo.2013.09.005 Zobrazit plný text záznamu Full Text from ScienceDirect